# Highly Functionalized 1,2–Diamino Compounds through Reductive Amination of Amino Acid-Derived β–Keto Esters

Paula Pérez-Faginas<sup>1</sup>, M. Teresa Aranda<sup>1</sup>, M. Teresa García-López<sup>1</sup>, Lourdes Infantes<sup>2</sup>, Asia Fernández-Carvajal<sup>3</sup>, José Manuel González-Ros<sup>3</sup>, Antonio Ferrer-Montiel<sup>3</sup>, Rosario González-Muñiz<sup>1</sup>\*

1 Instituto de Química-Médica, IQM-CSIC, Madrid, Spain, 2 Instituto de Química Física Rocasolano IQFR-CSIC, Madrid, Spain, 3 Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche, Spain

## Abstract

1,2-Diamine derivatives are valuable building blocks to heterocyclic compounds and important precursors of biologically relevant compounds. In this respect, amino acid-derived  $\beta$ -keto esters are a suitable starting point for the synthesis of  $\beta$ , $\gamma$ -diamino ester derivatives through a two-step reductive amination procedure with either simple amines or  $\alpha$ -amino esters. AcOH and NaBH<sub>3</sub>CN are the additive and reducing agents of choice. The stereoselectivity of the reaction is still an issue, due to the slow imine-enamine equilibria through which the reaction occurs, affording mixtures of diastereoisomers that can be chromatographically separated. Transformation of the  $\beta$ , $\gamma$ -diamino esters into pyrrolidinone derivatives allows the configuration assignment of the linear compounds, and constitutes an example of their potential application in the generation of molecular diversity.

Citation: Pérez-Faginas P, Aranda MT, García-López MT, Infantes L, Fernández-Carvajal A, et al. (2013) Highly Functionalized 1,2–Diamino Compounds through Reductive Amination of Amino Acid-Derived β–Keto Esters. PLoS ONE 8(1): e53231. doi:10.1371/journal.pone.0053231

Editor: Matthew H. Todd, University of Sydney, Australia

Received June 23, 2012; Accepted November 26, 2012; Published January 7, 2013

**Copyright:** © 2013 Pérez-Faginas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by the Spanish Ministry of Science and Innovation, SAF2009–09323 and Consolider-Ingenio CSD 2008–00005 (Spanish Ion Channel Initiative) and CSD2006–00015 (Crystallization Factory). P.P.-F. and M.T.A. thank the Consejo Superior de Investigaciones Científicas (CSIC) for a JAE-predoc fellowship and a JAEdoc contract, respectively, both from the Program Junta para la Ampliación de Estudios co-financed by the ESF. The funders had no role in study design, data collection and analysis, decision to publish, or the preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

\* E-mail: rosario.gonzalezmuniz@iqm.csic.es

## Introduction

Reductive amination of carbonyl compounds is one of the most useful and versatile methods for the synthesis of different kinds of amines, key intermediates in organic synthesis and in the preparation of important building blocks for drug discovery [1-3]. Reductive amination proceeds upon reaction of a carbonyl compound with ammonia, a primary amine or a secondary amine, through the formation of a carbinolamine, which normally dehydrates to form an imine or an iminium ion intermediate, followed by in situ reduction to the corresponding amine alkylated product [2]. The process could be direct, when all components and reactives are mixed without prior formation of intermediates, or indirect, with pre-formation of intermediates (imine/iminium/ enamine) and reduction in separate consecutive steps [3,4]. Regarding the reduction process, the most used methods are catalytic hydrogenation and hydride agents [1–4], although some other reagents have been developed [5-7]. Reductive amination of aldehydes and ketones with primary amines are typically easy, fast, and high-yielding reactions with many examples documented in the literature [1-4]. However difficulties have been described for some aromatic and acyclic ketones, with slower reaction rates and lower isolated yields than those found for alicyclic ketones and aldehydes [4]. The rate of reaction also depends on the steric and electronic factors of the reactant amine, and the process usually requires the addition of AcOH, the use of 5-10% excess of the amine, and a large excess of the reducing agent [3,4].

Examples of reductive amination using  $\beta$ -ketoesters as the carbonyl component are scarce, despite the final products,  $\beta$ amino acid derivatives, have interesting synthetic and biological applications [8,9]. A few reported examples describe the reduction of simple  $\beta$ -enamino esters by either catalytic hydrogenation or treatment with hydrides [10-12]. Other examples report the direct or indirect reductive amination of  $\beta$ -keto esters with ammonium acetate, different amines or the chiral ammonia equivalent  $\alpha$ methylbenzylamine [13-16]. In addition, both inter- and intramolecular processes have been applied to the efficient preparation of bioactive and natural compounds of high added value [17,18]. Despite the well documented use of amino acids in the reductive amination of aldehydes (i.e. in the formation of peptide reduced bonds) [19], to the best of our knowledge, only two reports describe the application of amino acid derivatives with ketones and  $\beta$ -keto esters [20,21]. In close relation to these precedents, we have previously studied the intramolecular reductive amination of Orn-derived  $\beta$ -keto esters (I,  $\mathbb{R}^1 = (\mathbb{CH}_2)_4 \mathbb{NH}_2$ ) and some dipeptide analogues for the preparation of piperidine and piperazine heterocycles [22,23]. These compounds were used as versatile chemical intermediates for the synthesis of highly substituted dioxoperhydropyrido[1,2-*c*]pyrimidine and trioxoperhydropyrazino[1,2-f]pyrimidine bicyclic systems [24,25], the former successfully used as the central core of selective CCK1 receptor antagonists. Owing to this versatility, we decided to investigate the intermolecular version of this process starting from amino

acid-derived  $\beta$ -ketoesters **I**. A suitable method for the reductive amination of compounds I could provide highly functionalized  $\beta$ ,  $\gamma$ -diamino esters **II** (Figure 1), which can be seen as interesting intermediates for the generation of molecular diversity (i.e., cyclization to different heterocyclic systems can easily be envisaged). Moreover, compounds II could bear additional reactive functions at  $\mathbf{R}^{1}$  (starting amino acid side-chain) and amine R<sup>3</sup> substituent, thus amplifying the possibilities of additional chemical manipulation. As the use of  $\beta$ -ketoesters in reductive amination processes is underdeveloped, many questions remain to be answered: Could amino acid-derived  $\beta$ -ketoesters **I** be applied to such an intermolecular process? Will the initial amino acid chiral center survive under the reductive amination conditions? Can amino acids be used as the amino component to incorporate additional complexity in final compounds? To answer these queries, we now describe our attempts to synthesize compounds **II**, through reductive amination, and the careful examination of the stereochemical issues.

## **Results and Discussion**

To explore the reaction between amino acid-derived  $\beta$ ketoesters and amines we selected compound **1**, easily prepared from Z-Phe-OH following a previously described method from our lab [26]. Two primary amines (BnNH<sub>2</sub> and *n*-BuNH<sub>2</sub>) and two  $\alpha$ amino esters (H-Ala-O'Bu and H-Gly-O'Bu) were chosen as amines for the reductive amination (Figure 2). H-Ala-O'Bu was selected for the initial exploratory study, since it could be the most demanding amino component. It is chiral, sterically congested due to  $\alpha$ -substitution, and the lower pKa of its amino group (calculated pKa = 7.82) should normally imply a weaker nucleophilic character, and hence a lower reactivity than simple alkyl/ benzyl amines (*n*-BuNH<sub>2</sub>, pKa = 10.87; BnNH<sub>2</sub>, pKa = 9.33).

Starting from **1** and H-Ala-O<sup>*t*</sup>Bu, we first investigated a battery of different conditions described for the reductive amination of ketones and  $\beta$ -keto esters, both using direct and indirect protocols. Direct reductive amination assays (Ti(O<sup>*t*</sup>Pr)<sub>4</sub> or AcOH as additive and NaBH<sub>3</sub>CN or NaBH(OAc)<sub>3</sub> as reducing agent failed, recovering the starting  $\beta$ -keto ester or leading to alcohols **2a,b** in different yield and diastereomeric ratio (Table S1, supporting information). Probably, the low reactivity of both carbonyl and



**Figure 1. Intermolecular reductive amination of amino acidderived β-ketoesters.** doi:10.1371/journal.pone.0053231.q001

amino species could take account for the disappointing results and, in fact, the diamino derivatives **3** were only detected, although in low yield, in the direct reaction at 50°C with AcOH/NaBH<sub>3</sub>CN. Using indirect procedures, first the reaction was allowed to stand at room temperature or at 50°C for the formation of the imine/ enamine intermediates (completion monitored by tlc), in the presence of different additives commonly used in reductive aminations [Ti(O<sup>i</sup>Pr)<sub>4</sub>, AcOH, CAN, LaCl<sub>3</sub>, ZnCl<sub>2</sub>] [20,27–30]. Then, NaBH<sub>3</sub>CN, NaBH(OAc)<sub>3</sub>, NaBH<sub>4</sub>, or H<sub>2</sub>/Pd-C were considered for the reduction of formed intermediates (Table S2, supporting information). The results of the two-step methods were more satisfactory, especially for the combination of AcOH and NaBH<sub>3</sub>CN, although the process required long reaction times, both for the intermediate formation and for the reduction step. Under the best conditions, (1. AcOH (1 equiv), CHCl<sub>3</sub>, 50°C; 2. NaBH<sub>3</sub>CN), the reaction of **1** and H-Ala-O<sup>t</sup>Bu afforded three diastereoisomeric compounds 3 (crude HPLC a:b:c ratio, 10:13:17), which were chromatographically separated and their configuration established as indicated later on. Although it has been pointed out that the reductive amination of  $\alpha$ -substituted  $\beta$ keto esters apparently occurs with control of the stereochemistry at both  $\alpha$  and  $\beta$ -positions [4], the formation of the 4*R*-configured isomer **3c** indicates that the stereochemical integrity at  $\gamma$ -position of the starting  $\beta$ -keto ester **1** was partially lost during the process. The reaction between 1 and H-Ala-O'Bu in the presence of  $Ti(O^{P}r)_{4}$ , followed by reduction with a mixture of NaBH(OAc)<sub>3</sub> and NaBH<sub>3</sub>CN, afforded low yield of diastereoisomers **3a** and **3b**, along with alcohols **2a,b** as major products. In this case, the lack of 3c suggests that most probably the intermediate species for reduction are hemiaminal titanate derivatives and not imine/ enamine species [27]. In fact, the imine/enamine intermediates were detected by HPLC-MS in the Ti(O<sup>i</sup>Pr)<sub>4</sub>-promoted reactions in MeOH but not in the experiments performed in aprotic solvents (dichloromethane and dichloroethane, Table S2). Unfortunately, an attempt to optimize this Ti(O<sup>i</sup>Pr)<sub>4</sub>-mediated process, which included heating the mixture of the ketoester and the amine in neat Ti(O<sup>*i*</sup>Pr)<sub>4</sub> (no solvent), was unsuccessful (Table S2, entry 8). The assay to reduce the preformed imine/enamine intermediates in the presence of a heterogeneous hydrogenation catalyst (Pd-C, 50°C, 45 psi), a method that have worked very well for other substrates [23,31], was also unproductive in this case, resulting in the partial reversion to the initial  $\beta$ -ketoester (Table S2, entry 17).

Application of the AcOH/NaBH<sub>3</sub>CN optimized conditions to the reaction of 1 with H-Gly-O'Bu resulted in an approximately 1:1 mixture of the expected diastereoisomers 4a and 4b (Figure 2, Table 1). Almost equimolecular mixtures of 3S,4S and 3R,4S diastereoisomers were also formed in the reaction with benzyl and butyl amines, although the total yield of the corresponding compounds 5a,b and 6a,b were slightly lower than those obtained with amino acids. Taking into account the higher pKa of these amines in relation to amino esters, this result seems to suggest that the amino acid-derived  $\beta$ -keto ester is the principal responsible of the low reactivity found. We might speculate that the existence of the ZNH group at the  $\gamma$ -position, neighboring to the reactive carbonyl, hampers the attack of the amine component. Finally, according to chiral HPLC experiments, compounds 4-6 were obtained as racemic mixtures, while a 70:30 ratio of enantiomers was observed for Ala derivatives 3a-c (Figures S1 and S2).

To provide some insight into the mechanism of the two-step reductive amination process, we follow first the formation of reaction intermediates by <sup>1</sup>H NMR. The reaction of **1** and H-Gly-O'Bu in CDCl<sub>3</sub> and AcOH (1 equiv) gave a mixture of *E* and  $\mathcal{Z}$  enamines **B1** and **B2** in a 3:4 ratio, as deduced from the singlet



Figure 2. Synthetic procedure for  $\beta_{\gamma}$ -diamino esters by reductive amination of Phe-derived  $\beta$ -ketoester 1. doi:10.1371/journal.pone.0053231.g002

signals at 4.68 and 4.45 ppm, respectively [29] (Figure S3). However the spectrum of the crude reaction with H-Ala-O'Bu showed four signals of enamine proton (at 4.68, 4.62, 4.56 and 4.52 ppm, relative ratio 5:8:9:11), which were supposed to be two E- (**B1** and **B1'**) and two Z-isomers (**B2** and **B2'**), having 4S and 4R-configuration. From this result, we reasoned that the initially formed imines **A** should isomerize to the most stable conjugated enamines **B**, and that enamines **C** should also be present in the equilibrium and could be responsible for the stereochemical integrity loss (Figure 3). The observed epimerization at the 1'position of final diamino esters indicated that conjugated-imines **D** must also be present among the possible intermediates of the reaction. While the imine-enamine tautomerism  $(A \leftrightarrow B \text{ and/or})$  $A \leftrightarrow C$ ) was expected to occur in some extent, as previously reported for intramolecular processes [24,32], the A↔D interconversion was unanticipated, since the chiral integrity of the amino acid derivative acting as the amino component is normally preserved in reductive amination reactions of  $\alpha$ -amino esters with aldehydes,  $\alpha$ -aminoaldehydes and even ketones [33–36].

When the intermediates formed between 1 and H-Ala-O'Bu or H-Gly-O'Bu were reduced with NaBD<sub>3</sub>CN the measured incorporation of deuterium (Table 2) corroborated the presence of intermediates **B**, **C** and **D**, although imines **A** are predominantly reduced by the hydride, as deduced from the high percentage of deuterium found at position 3 (Figures S4 and S5). The formation of all possible intermediates could be favored by the temperature

**Table 1.** Result of the reductive amination of Phe-derived  $\beta$ -ketoester **1**.

Final Compd.	Diastereoisomer (%) <sup>a</sup>				
	а	b	c		
3	18	20	30		
4	33	34	-		
5	16	19	-		
6	23	27	-		

<sup>a</sup>Yield of isolated compounds.

doi:10.1371/journal.pone.0053231.t001

PLOS ONE | www.plosone.org

and long times needed in the first step, due to the low reactivity of the starting materials, and to the slow speed of reduction in the second. Here, the more stable conjugated enamines **B** are reduced in low extent, but the transitory short-life imine **A** is the main intermediate trapped by the hydride.

In the <sup>1</sup>H NMR spectra, compounds **3a**, **3c** and **4a** showed a small value of the 3.4 coupling constant (0-2.9 Hz), indicating a preferred conformation in which the 3 and 4 protons form a dihedral angle close to  $90^{\circ}$ , while for isomers **b** this 7 value is higher (~6.2 Hz). Although simple Chem3D calculation suggested a three disposition for isomers **a** and **c** and erythree for **b**, this data did not afford any conclusive experimental information about the configuration at C3 and C4 chiral centers. The configurational assignment was done in an indirect way through the formation of pyrrolidinone derivatives. To this end, compounds 3 and 4 were deprotected at the 4-NH group and cyclized to the corresponding five-membered heterocycles 7 and 8, respectively (Figure 4). These cyclic compounds can illustrate one example of the application of the described diamino esters in the creation of diverse heterocyclic scaffolds of interest. Related pyrrolidinone derivatives, having an unsubstituted 4-amino group, have been prepared through the Zinc-mediated homologation of  $\alpha$ -aminonitriles and subsequent acidic hydrolysis [37]. The  $\mathcal{J}_{4,5}$  in derivatives **7a**, **7c** and **8a**  $(\sim 6.5 \text{ Hz})$  was higher than in their corresponding distereoisomers **7b** and **8b** ( $\sim$ 4.5 ppm). Knowing that in this type of heterocyclic system the coupling constant are  $\mathcal{J}_{anti} < \mathcal{J}_{syn}$  [38], we can anticipate the *syn*- and *anti*-relative stereochemistry for isomers  $\mathbf{a}$  ( $\mathbf{c}$ ) and  $\mathbf{b}$ , respectively. Similarly, NOE experiments indicated a syn-relationship between H4 and H5 protons in 7a, 7c and 8a and an antidisposition in the respective isomers **b**. The exclusive formation of isomers **3a** and **3b** in a  $Ti(O^{i}Pr)_{4}$  experiment, which probably occurs through titanate intermediates, allowed to distinguish between 3a and 3c syn-diastereoisomers. 4,5-Syn- and 4,5-antipyrrolidinones showed a different pattern of chemical shifts in <sup>13</sup>C-NMR, with C-4, C-5, and especially 5-CH<sub>2</sub> carbons notoriously shielded for syn-isomers a and c (~55, 59, and 36 ppm) [39] with respect to their corresponding anti analogues b (57.5, 62, and 41 ppm). Just the opposite behavior was observed for the C-5 carbon in the linear precursors 3 and 4, for which the most shielded signal corresponds to the *threo*-isomers **b** ( $\sim$ 37 ppm for three, and  $\sim 39$  ppm for erithree). A comparison of these values with



**Figure 3. Reaction Intermediates.** Possible intermediates in the reductive amination of **1** with H-Gly-O<sup>t</sup>Bu ( $R^1 = H$ ) or H-Ala-O<sup>t</sup>Bu ( $R^1 = Me$ ). For clarity, only 4S and 1'S isomers are depicted (**A–D**), but 4R and 1'R containing intermediates (**A'–D'**) are also possible if all the indicated species are present in equilibrium. doi:10.1371/journal.pone.0053231.g003

those of  $J_{3,4}$  between distereoisomers **a** and **b** in compounds **5** and **6** allowed us the stereochemical assignment of these compounds.

Fortunately, we succeed in getting crystal structures of a couple of the pyrrolidinone derivatives, 7a and 7b, corroborating the *sym* 

Final Compd.	%D <sup>a</sup>					
	H2	H3	H4	H1′		
3a	11	>90	5	4		
3b	5	>90	3	6		
3c	10	>90	5	3		
4a	4	>90	4	5		
4b	3	>90	3	5.5		

**Table 2.** Incorporation of deuterium in the reduction with NaBD<sub>3</sub>CN.

<sup>a</sup>Measured by <sup>1</sup>H NMR (d1 = 10) in CDCl<sub>3</sub> at 25°C. Reduction of imines **A**: incorporation of D at H3; Enamines **B**: D at H2, H3; Enamines **C**: D at H3, H4; Imines **D**: D at H1'.

doi:10.1371/journal.pone.0053231.t002

and anti disposition between substituents at 4 and 5 positions in these compound, and hence the previous assignment performed by NMR (Figures 5 and 6). Structures have been deposited at the Cambridge Crystallographic Data Centre, CCDC number: 880360 (7a) and 877464 (7b). Despite the 70:30 enantiomeric mixture observed in chiral HPLC of these compounds, each crystal contains a racemic 1:1 mixture of enantiomers. For 7a, these enantiomers, related by a pseudocenter of symmetry [40], are forming dimers through N101-H101...O201 and N201-H201...O101 hydrogen bonds. Strong chains are created via a number of  $CH...\pi$  and CH...O = C contacts (C104-H104...Cen2, C103-H103...Cen2, C204-H204...Cen1, C203-H203...Cen1, C105-H105...O101, C205-H205...O201). These chains form (001) layers through CH... $\pi$  interactions and the 3D structure is build up through CH...O = C contacts and Van der Waals interactions between the tert-butyl groups (Figure S6). For **7b**, the enantiomers, related by a center of symmetry, form dimers through N1-H1...O1 strong hydrogen bonds. These dimers are joined (N2-H2...O2) to form chains along the ac diagonal. These chains form (10-1) sheets through CH...O weak interactions (C10-H10a...O1 and C13-H132...O1). The crystal is formed by the union of these sheets through CH... $\pi$  (C12-H12A...CenPh) contacts (Figure S7).



**Figure 4. Synthetic procedure for 4,5-disubstituted 2-pyrrodinones from** β,γ-**diamino ester derivatives.** doi:10.1371/journal.pone.0053231.g004

#### Conclusions

In summary, we describe a procedure for the preparation of  $\beta$ , $\gamma$ -diamino esters from reaction of amino acid-derived  $\beta$ -ketoesters with both simple amines as well as  $\alpha$ -amino esters. To the best of our knowledge, this represents the first reductive amination protocol ever described using amino acid-derived  $\beta$ -ketoesters. This requires a first step of formation of intermediates with AcOH, and the subsequent reduction with NaBH<sub>3</sub>CN. In this method, the diastero- and enantioselectivities were compromised by the existence of different imine-enamine equilibria, as demonstrated by <sup>1</sup>H NMR and deuteration experiments. These equilibria are favored by the long reaction times required, probably derived from the low reactivity of the hindered carbonyl component. The separated diastereoisomeric  $\beta$ , $\gamma$ -diamino esters can be transformed into the corresponding pyrrolidinone derivatives by cyclization between the 4-amino and the 1-carboxylate



**Figure 5. X-Ray molecular structure of 2-pyrrolidinone derivative 4R\*,5R\*-7a.** Atom labeling for molecule 1 or 2 can be obtained by adding 100 or 200 respectively to the label of the atom shown in this figure, *i.e.* O1 is labelled O101 in molecule 1 and O201 in molecule 2. Thermal ellipsoids are drawn at 50% probability level of non-H atoms, and the H atoms are denoted as spheres of 0.1 Å radius. doi:10.1371/journal.pone.0053231.q005

groups. These pyrrolidinones serve as reliable clue in the configurational assignment (NMR, X-ray) of the linear precursors, and represent a first example of the potential of the described diamino esters for the preparation of different heterocycles.

## **Materials and Methods**

All reagents were of commercial quality. Solvents were dried and purified according to standard methods. Flash chromatography was performed on silica gel 60 (230–400 mesh). NMR spectra were recorded on spectrometers operating at 300 and 75 MHz for <sup>1</sup>H and <sup>13</sup>C, respectively, using TMS as internal standard (Figure S8). Chemical shifts are given in ppm and  $\mathcal{J}$  values in Hz. The C attributions are supported by HSQC experiments. Electrospray mass spectra (positive mode) were also recorded. Analytical HPLC were performed on a Eclipse Plus C<sub>18</sub> (5 µm, 4.6×150 mm) column using a UV detector at 220 nm. Mixtures of CH<sub>3</sub>CN (0.05% TFA, solvent A) and H<sub>2</sub>O (solvent B) were used in the mobile phase, and the corresponding mixture was specified in each



**Figure 6. X-Ray molecular structure of 2-pyrrolidinone derivative 4R\*,55\*-7b showing the atomic numbering scheme.** Thermal ellipsoids are drawn at 50% probability level of non-H atoms, and the H atoms are denoted as spheres of 0.1 Å radius. doi:10.1371/journal.pone.0053231.g006

case (flow rate 1 mL/min). HPLC-MS, performed in a X-Bridge C<sub>18</sub> (3.5  $\mu$ m, 2.1×100 mm) column; eluent CH<sub>3</sub>CN (0.08% formic acid, solvent A) and H<sub>2</sub>O (0.1% formic acid, solvent B); flow rate 0.5 mL/min. Chiral HPLC was performed on a Chiralpak IA column (0.4×25 cm) using the mixtures of solvents indicated in each case (isocratic conditions).  $\beta$ -Ketoester **1** was prepared as previously described [41,42].

#### General Procedure for the Reductive Amination

Method A (One step-procedure). To a stirred solution of  $\beta$ ketoester **1** (57 mg, 0.15 mmol) in the appropriate solvent (2 mL), H-Ala-O'Bu (0.30 mmol), TEA (41 µL, 0.30 mmol) the corresponding additive (0.5–2 equiv.) and the reducing agent (20 mg, 0.30 mmol) were added. The mixture was stirred at room temperature or 50°C for 1–3 days. After evaporation, the residue was dissolved in EtOAc and washed with 10% NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum. The resulting residue was monitored by HPLC-MS (Table S1), and in one case purified on a silica gel column using hexane:EtOAc 4:1 to characterize alcohol derivatives **2**.

## (3*R*,4*S*)-Methyl 4-(benzyloxycarbonyl)amino-3-hydroxy-5phenylpentanoate (2a)

HPLC  $t_{\rm R} = 10.78$  min (X-Bridge, gradient 20–100 ACN in 15 min.). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.44–7.12 (m, 10H, Ar), 5.22 (bd, 1H,  $\mathcal{J}$ = 7.4, NH Z), 5.11 and 5.06 (d, 1H,  $\mathcal{J}$ = 12.4 Hz, CH<sub>2</sub> Z ), 4.01 (bd, 1H,  $\mathcal{J}$ = 9.6, 3-H), 3.82 (q, 1H,  $\mathcal{J}$ = 7.9, 4-H), 3.67 (s, 3H, OCH<sub>3</sub>), 3.42 (bs, 1H, OH), 2.94 (bd, 2H,  $\mathcal{J}$ = 7.6, 2-H), 2.59 (dd, 1H,  $\mathcal{J}$ = 16.9, 10.2, 5-H), 2.39 (dd, 1H,  $\mathcal{J}$ = 16.9, 2.3, 5-H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ:173.8 (CO<sub>2</sub>), 156.3 (CO Z), 137.9, 136.5 (C Ar), 129.4, 128.6, 128.5, 128.1, 127.9, 126.5 (CH Ar), 66.9 (3-C), 66.8 (CH<sub>2</sub> Z), 55.9 (4-C), 51.9 (OCH<sub>3</sub>), 38.6 (2-C), 38.3 (5-C). [α]<sub>D</sub> = +12.5 (*c*, 0.8 MeOH).

## (35,45)-Methyl 4-(benzyloxycarbonyl)amino-3-hydroxy-5phenylpentanoate (2b)

Mp: 123–126°C. HPLC  $t_{\rm R} = 10.5$  min (X-Bridge, gradient 20– 100 ACN in 15 min.). <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$ : 7.46–7.10 (m, 10H, Ar), 5.02 (s, 2H, CH<sub>2</sub> Z) 4.82 (m, 1H, NH Z), 4.03 (m, 1H, 3-H), 3.95 (m, 1H, 4-H), 3.71 (s, 3H, OCH<sub>3</sub>), 3.48 (bs, 1H, OH), 3.00 (dd, 1H,  $\mathcal{J}$ = 14.1, 4.5, 5-H), 2.86 (m, 1H, 5-H), 2.60 (dd, 1H,  $\mathcal{J}$ = 16.6, 3.5, 2-H), 2.52 (dd, 1H,  $\mathcal{J}$ = 16.6, 8.6, 2-H). <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ :173.2 (CO<sub>2</sub>), 156.1 (CO Z), 137.3, 136.3 (C Ar), 129.4, 128.5, 128.4, 128.0, 127.9, 126.5 (CH Ar), 69.9 (3-C), 66.7 (CH<sub>2</sub> Z), 55.8 (4-C), 51.9 (OCH<sub>3</sub>), 38.0 (5-C), 35.6 (2-C). [ $\alpha$ ] = -40.0 (c, 0.5 MeOH). Described: [ $\alpha$ ]<sub>D</sub> = -45.5 (c, 1 MeOH) [43].

Method B (Two step-procedure, AcOH). To a stirred solution of  $\beta$ -ketoester **1** (0.57 g, 1.6 mmol) in CHCl<sub>3</sub> (10 mL), the corresponding amine (4.8 mmol) and AcOH (91 µL, 1.6 mmol) were added. In the case of amino acid derivatives, the amino group was released from the HCl salt by addition of TEA (0.66 mL, 4.8 mmol). The mixture was stirred at 50°C until the total formation of imine/enamine intermediates was observed. Then, NaBH<sub>3</sub>CN (0.2 g, 3.2 mmol) was added, and the mixture was stirred at room temperature until complete reduction of the imine/enamine intermediates. After evaporation, the residue was dissolved in EtOAc and washed with 10% NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum. The resulting residue was purified on a silica gel column using the solvent system indicated in each case.

Method C (Two step-procedure,  $Ti(O^iPr)_4$ ). To a stirred solution of  $\beta$ -ketoester **1** (0.1 g, 0.28 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL), was added a solution of H-Ala-O'Bu.HCl (0.218 mmol) and TEA

(0.218 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL). The mixture was stirred at room temperature overnight. Then the reaction was cooled to 0°C and NaBH<sub>3</sub>CN (0.563 mmol) and NaBH(OAc)<sub>3</sub> (0.563 mmol) were added. The reaction was stirred overnight. After evaporation, the residue was solved in EtOAc and was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum. The resulting residue was purified on a silica gel column using EtOAc:hexane (1:8 to 1:4) as eluents. Alcohols **2a** (47.3 mg) and **2b** (27.2 mg) were isolated along with compounds **3a** (8.8 mg) and **3b** (5.6 mg).

Methyl 4-(benzyloxycarbonyl)amino-3-[1'-(tertbutoxycarbonyl)ethan-1'-yl]amino-5-phenylpentanoate (3). 3a (35\*,45\*,1'5\*). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, Diastereomer 1:1:2). Yield: 18% (syrup). HPLC  $t_{\rm R} = 13.66$  min (5 to 100% A in 15 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.37-7.10 (m, 10H, Ar), 5.15 (d, 1H, 7=9.4 Hz, 4-NH), 5.05, 4.98 (AB system, 2H, 7=12.2 Hz,  $CH_2$  Z), 3.96 (q, 1H,  $\mathcal{J} = 7.6$  Hz, 4-H), 3.61 (s, 3H, OCH<sub>3</sub>), 3.29 (q, 1H, *J* = 7.0 Hz, 1'-H), 2.99 (dd, 1H, *J* = 6.9, 5.7 Hz, 3-H), 2.84 (d, 2H, 7 = 7.6 Hz, 5-H), 2.51 (dd, 2H, 7 = 15.2, 6.9 Hz, 2-H), 2.44(dd, 2H, 7=15.2, 5.7 Hz, 2-H),1.73 (bs, 1H, 3-NH), 1.44 (s, 9H,  $CH_3$  <sup>t</sup>Bu), 1.24 (d, 3H,  $\mathcal{J} = 7.0$  Hz, 2'-H). <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ : 175.3, 172.0 (CO<sub>2</sub>), 156.1 (CO Z), 138.0, 136.6 (C Ar), 129.1, 128.4, 128.3, 127.9, 126.3 (CH Ar), 81.2 (C <sup>t</sup>Bu), 66.5 (CH<sub>2</sub> Z), 57.2 (3-C), 55.6 (4-C), 54.8 (1'-C), 51.6 (OMe), 39.1 (5-C), 38.1 (2-C), 27.9 (CH<sub>3</sub> <sup>t</sup>Bu), 20.0 (2'-C). MS: 485.5  $[M+1]^+$ . Anal. cal. for C<sub>27</sub>H<sub>36</sub>N<sub>2</sub>O<sub>6</sub>: C 66.92, H 7.49, N 5.78, found C 66.88, H 7.51, N 5.65

Diastereomer 3b (3R\*,4S\*,1'S\*). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, 1:1:2). Yield: 20% (syrup). HPLC  $t_R = 12.55 \text{ min}$  (5 to 100% A in 15 min).<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ:7.32-7.19 (m, 10H, Ar), 5.34 (d, 1H, f = 7.8 Hz, 4-NH), 5.02 and 4.97 (AB system, 2H,  $\mathcal{J} = 12.6 \text{ Hz}, \text{ C}H_2 \text{ Z}), 3.99 \text{ (m, 1H, 4-}H), 3.65 \text{ (s, 3H, OC}H_3),$ 3.32 (q, 1H, *j* = 6.8 Hz, 1'-H), 3.13 (q, 1H, *j* = 6.3 Hz, 3-H), 2.94 (dd, 1H, 7 = 13.8, 5.3 Hz, 5-H), 2.78 (dd, 1H, 7 = 13.8, 8.8 Hz, 5-*H*), 2.51 (dd, 1H,  $\tilde{\gamma}$  = 15.3, 5.8 Hz, 2-*H*), 2.78 (dd, 1H,  $\tilde{\gamma}$  = 15.3, 6.9 Hz, 2-H), 1.68 (bs, 1H, 3-NH), 1.43 (s, 9H, CH<sub>3</sub> <sup>t</sup>Bu),1.21 (d, 3H, f = 6.8 Hz, 2'-H).<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ : 174.9, 172.5 (CO<sub>2</sub>), 156.1 (CO Z), 137.9, 136.7(C Ar), 129.2, 128.4, 128.3, 127.8, 127.7, 126.4 (CH Ar), 81.1 (C(CH<sub>3</sub>)<sub>3</sub>), 66.4 (CH<sub>2</sub> Z), 56.8 (3-C), 55.4 (1'-C and 4-C), 51.7 (OCH<sub>3</sub>), 37.15 (5-C), 37.1 (2-C), 27.9  $(C(CH_3)_3)$ , 19.6 (2'-C). MS: 485.5  $[M+1]^+$ . Anal. cal. for C<sub>27</sub>H<sub>36</sub>N<sub>2</sub>O<sub>6</sub>: C 66.92, H 7.49, N 5.78, found C 66.67, H 7.83, N 5.72.

Diastereomer 3c (35\*,45\*,1'R\*). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, 1:1:2). Yield: 30% (syrup). HPLC  $t_R = 12.90 \text{ min}$  (5 to 100% A in 15 min).<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ:7.32-7.19 (m, 10H, Ar), 5.35 (d, 1H, *j*=8.7 Hz, 4-NH), 5.07 and 5.00 (AB system, 2H,  $\mathcal{J} = 12.3 \text{ Hz}, \text{ C}H_2 \text{ Z}), 3.95 \text{ (m, 1H, 4-H)}, 3.61 \text{ (s, 3H, OC}H_3),$ 3.27 (q, 1H, 7 = 6.9 Hz, 1'-H), 3.12 (dt, 1H, 7 = 6.3, 2.9 Hz, 3-H),2.93 (dd, 1H,  $\tilde{j}$ =13.7, 6.3 Hz, 5-H), 2.81 (dd, 1H,  $\tilde{j}$ =13.7, 7.7 Hz, 5-H), 2.48 (dd, 1H, 7=15.1, 6.7 Hz, 2-H), 2.40 (dd, 1H,  $\mathcal{J} = 15.1, 6.4 \text{ Hz}, 2-H$ , 1.73 (bs, 1H, 3-NH), 1.45 (s, 9H, CH<sub>3</sub> <sup>t</sup>Bu), 1.23 (d, 3H, 7 = 6.9 Hz, 2'-H).<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ : 174.9, 172.3 (CO<sub>2</sub>), 156.1 (CO Z), 137.8, 136.6 (C Ar), 129.3, 129.1, 128.4, 128.3, 127.9, 127.8, 126.3 (CH Ar), 81.2 (C(CH<sub>3</sub>)<sub>3</sub>), 66.5 (CH<sub>2</sub> Z), 55.5 (4-C), 55.1 (1'-C), 54.4 (3-C), 51.5 (OCH<sub>3</sub>), 38.3 (5-C), 37.3 (2-C), 27.9 (C(CH<sub>3</sub>)<sub>3</sub>), 19.7 (2'-C). MS: 485.5  $[M+1]^+$ . Anal. cal. for C<sub>27</sub>H<sub>36</sub>N<sub>2</sub>O<sub>6</sub>: C 66.92, H 7.49, N 5.78, found C 66.90, H 7.35, N 5.51

 
 Methyl
 4-(benzyloxycarbonyl)amino-3-[(tertbutoxycarbonyl)methyl]amino-5-phenylpentanoate
 (4).

 Diastereomer 4a (3S\*,4S\*).
  $(CH_2Cl_2:Et_2O:hexane, 1:1:3 to 1:1:1)$ . Yield: 33% (syrup). HPLC  $t_R = 12.33 min (20 to 100\% A in 20 min)$ .
 <sup>1</sup>H NMR (CDCl\_3) & 7.35-7.21 (m, 10H, Ar), 5.20 (bd, 1H,  $\mathcal{J} = 9.1$  Hz, 4-NH), 5.06 and 4.99 (AB system, 2H,
 
$$\begin{split} & \mathcal{J} = 12.4 \text{ Hz}, \text{C}H_2 \text{ Z}), 3.97 \text{ (m, 1H, 4-}H), 3.63 \text{ (s, 3H, OC}H_3), 3.36 \\ & (\text{s, 2H, C}H_2 \text{ Gly}), 3.03 \text{ (dt, 1H, }\mathcal{J} = 6.7, 2.2 \text{ Hz}, 3-}H), 2.87 \text{ (dq, 2H, } \\ & \mathcal{J} = 13.7, 7.4 \text{ Hz}, 5-}H), 2.47 \text{ (m, 2H, 2-}H), 1.60 \text{ (bs, 1H, 3-}NH), \\ & 1.46 \text{ (s, 9H, C}H_3 \text{ 'Bu}). \text{ }^{13}\text{C} \text{ NMR (CDCl_3) } \delta: 174.4 \text{ and } 173.5 \\ & (\text{CO}_2), 157.9 \text{ (CO Z)}, 139.6, 137.9, 136.6, 129.2, 128.4, 127.9, \\ & 127.8, 126.4 \text{ (C and CH Ar)}, 81.5 \text{ (C 'Bu)}, 66.5 \text{ (CH}_2 \text{ Z}), 56.1 (3-}C), \\ & 55.6 \text{ (4-}C), 51.7 \text{ (OCH}_3), 51.0 \text{ (CH}_2 \text{ Gly)}, 38.7 \text{ (5-}C), 37.6 \text{ (2-}C), \\ & 28.0 \text{ (CH}_3 \text{ 'Bu)}. \text{ MS: } 471.3 \text{ [M+1]}^+, 493.3 \text{ [M+23]}^+. \text{ Anal. cal. for } \\ & \text{C}_{26}\text{H}_{34}\text{N}_2\text{O}_6\text{: C } 66.36, \text{H } 7.28, \text{N } 5.95, \text{ found C } 66.55, \text{H } 7.14, \text{N } \\ & 5.75. \end{split}$$

**Diastereomer 4b (3***R***\*,4***S***\*). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, 1:1:3 to 1.1:1). Yield: 34% (solid). HPLC t\_{\rm R} = 12.52 min (20 to 100% A in 20 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>) \delta: 7.33–7.18 (m, 10H, Ar), 5.15 (d, 1H, \mathcal{J} = 9.2 Hz, 4-N***H***), 5.00 (m, 2H, C***H***<sub>2</sub> Z), 4.01 (m, 1H, 4-***H***), 3.66 (s, 3H, OC***H***<sub>3</sub>), 3.38 and 3.22 (AB system, 2H, \mathcal{J} = 17.4 Hz, C***H***<sub>2</sub> Gly), 3.09 (q, 1H, \mathcal{J} = 6.1 Hz, 3-***H***), 2.93 (dd, 1H, \mathcal{J} = 13.9, 5.1 Hz, 5-***H***), 2.79 (m, 1H, 5-***H***<sub>2</sub>), 2.50 (m, 2H, 2-***H***), 1.45 (s, 9H, C***H***<sub>3</sub> 'Bu). <sup>13</sup>C NMR (CDCl<sub>3</sub>) \delta: 172.5 and 171.7 (CO<sub>2</sub>), 156.0 (CO Z), 137.8, 136.6, 129.2, 128.4, 128.3, 127.9, 127.8, 126.4 (C and CH Ar), 81.3 (C 'Bu), 66.4 (CH<sub>2</sub> Z), 57.8 (3-C), 55.0 (4-C), 51.8 (OCH<sub>3</sub>), 49.9 (CH<sub>2</sub> Gly), 37.1 (5-C), 36.6 (2-C), 28.0 (CH<sub>3</sub> 'Bu). MS: 471.3 [M+1]<sup>+</sup>, 493.3 [M+23]<sup>+</sup>. Anal. cal. for C<sub>26</sub>H<sub>34</sub>N<sub>2</sub>O<sub>6</sub>: C 66.36, H 7.28, N 5.95, found C 66.58, H 7.39, N 5.62.** 

Methyl 3-benzylamino-4-(benzyloxycarbonyl)amino-5phenylpentanoate Diastereomer (5). 5a (3S\*,4S\*). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, 1:1:2). Yield: 16% (syrup). HPLC  $t_{\rm R} = 8.02 \text{ min} (20 \text{ to } 100\% \text{ A in } 20 \text{ min}).$ <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.37-7.11 (m, 15H, Ar), 5.20 (bs, 1H, 4-NH), 5.05 and 5.00 (AB system, 2H, 7=12.0 Hz, CH<sub>2</sub> Z), 4.01 (m, 1H, 4-H), 3.87 and 3.72 (AB system, 2H, 7=12.7 Hz, CH<sub>2</sub> N-Bn), 3.62 (s, 3H, OCH<sub>3</sub>), 3.11 (m, 1H, 3-H), 2.87 (m, 2H, 5-H), 2.49 (m, 2H, 2-H), 1.60 (bs, 1H, 3-NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ: 172.3 (CO<sub>2</sub>), 156.2 (CO Z), 137.9, 136.4, 129.1, 128.5, 128.4, 128.0, 127.9, 127.4, 126.4 (C and CH Ar), 66.6 (CH<sub>2</sub> Z), 55.9 (4-C), 55.6 (3-C), 52.7 (CH<sub>2</sub> Bn), 51.7 (OCH<sub>3</sub>), 38.8 (5-C), 31.7 (2-C). MS: 447.3 [M+1]<sup>+</sup>. Anal. cal. for C<sub>27</sub>H<sub>30</sub>N<sub>2</sub>O<sub>4</sub>: C 72.62, H 6.77, N 6.27, found C 72.29, H 6.82, N 5.93.

**Diastereomer 5b** ( $3R^*, 4S^*$ ). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, 1:1:2). Yield: 19% (solid). HPLC  $t_R = 8.03 \text{ min}$  (20 to 100% A in 20 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$ :7.34–7.15 (m, 15H, Ar), 5.03 (m, 2H, CH<sub>2</sub> Z), 4.92 (d, 1H,  $\mathcal{J} = 9.3$  Hz, 4-NH), 4.11 (m, 1H, 4-H), 3.81 (s, 2H, CH<sub>2</sub> N-Bn), 3.64 (s, 3H, OCH<sub>3</sub>), 3.11 (m, 1H, 3-H), 2.94 (dd, 1H,  $\mathcal{J} = 13.9$ , 5.2 Hz, 5-H), 2.78 (m, 1H, 5-H), 2.54 (m, 2H, 2-H). <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ : 172.7 (CO<sub>2</sub>), 156.2 (CO Z), 140.0, 137.8, 136.5, 129.2, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.0, 126.5 (C and CH Ar), 66.6 (CH<sub>2</sub> Z), 56.8 (3-C), 54.5 (4-C), 51.8 (OCH<sub>3</sub>), 51.2 (CH<sub>2</sub> N-Bn), 37.7 (5-C), 35.9 (2-C). MS: 447.3 [M+1]<sup>+</sup>, 469.2 [M+23]<sup>+</sup>. Anal. cal. for C<sub>27</sub>H<sub>30</sub>N<sub>2</sub>O<sub>4</sub>: C 72.62, H 6.77, N 6.27, found C 72.47, H 6.95, N 6.05.

Methyl 4-(benzyloxycarbonyl)amino-3-butylamino-5phenylpentanoate Diastereomer (6). 6a (3S\*,4S\*). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, 1:1:2). Yield: 23% (syrup). HPLC  $t_{\rm R} = 7.52 \text{ min} (20 \text{ to } 100\% \text{ A in } 20 \text{ min})$ . <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.35-7.19 (m, 10H, Ar), 5.12 (d, 1H, *j*=8.0 Hz, 4-NH), 5.06 and 5.00 (AB system, 2H, 7 = 12.0 Hz, CH<sub>2</sub> Z), 3.96 (m, 1H, 4-H), 3.63 (s, 3H, OCH<sub>3</sub>), 3.02 (m, 1H, 3-H), 2.87 (m, 2H, 5-H), 2.69 (m, 1H, 4-CH<sub>2</sub> Bu), 2.54 (dt, 1H,  $\mathcal{J}$ =11.1, 5.2 Hz, 4-CH<sub>2</sub> Bu), 2.44 (m, 2H, 2-H), 1.44-1.26 (m, 4H, 2- and 3-CH2 Bu), 1.20 (bs, 1H, 3-NH), 0.91 (t, 3H, f = 7.1 Hz, CH<sub>3</sub> Bu). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ: 172.5 (CO<sub>2</sub>), 156.2 (CO Z), 138.1, 136.6, 129.2, 128.5, 128.4, 128.0, 127.9, 126.4 (C and CH Ar), 66.6 (CH<sub>2</sub> Z), 56.1 (3-C), 55.6 (4-C), 51.7 (OCH<sub>3</sub>), 48.5 (4-CH<sub>2</sub> Bu), 38.8 (5-C), 37.3 (2-C), 32.7 (3- $CH_2$  Bu), 20.3 (2- $CH_2$  Bu), 13.9 ( $CH_3$  Bu). MS: 413.3 [M+1]<sup>+</sup>.

Anal. cal. for  $\rm C_{24}H_{32}N_2O_4{:}$  C 69.88, H 7.82, N 6.79, found C 70.18, H 7.61, N 6.80.

**Diastereomer 6b** (3*R*\*,4*S*\*). (CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O:hexane, 1:1:3). Yield: 27% (syrup). HPLC  $t_{\rm R}$  = 7.72 min (20 to 100% A in 20 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>) &: 7.34-7.17 (m, 10H, Ar), 5.01 (m, 2H, CH<sub>2</sub> Z), 4.92 (d, 1H,  $\mathcal{J}$ = 9.2 Hz, 4-NH), 4.02 (m, 1H, 4-H), 3.65 (s, 3H, OCH<sub>3</sub>), 3.03 (q, 1H,  $\mathcal{J}$ = 6.2 Hz, 3-H), 2.94 (dd, 1H,  $\mathcal{J}$ = 13.8, 5.2 Hz, 5-H), 2.79 (m, 1H, 5-H), 2.59 (m, 2H, 4-CH<sub>2</sub> Bu), 2.50 (m, 2H, 2-H), 1.44-1.26 (m, 5H, 3-NH, 2- and 3-CH<sub>2</sub> Bu), 0.89 (t, 3H,  $\mathcal{J}$ = 7.1 Hz, CH<sub>3</sub> Bu). <sup>13</sup>C NMR (CDCl<sub>3</sub>) &: 172.9 (CO<sub>2</sub>), 156.1 (CO Z), 137.9, 136.6, 129.0, 128.5, 128.4, 128.0, 127.9, 126.4 (C Ar), 66.6 (CH<sub>2</sub>(Z)), 57.6 (3-C), 54.7 (4-C), 51.7 (OCH<sub>3</sub>), 46.8 (4-CH<sub>2</sub> Bu), 37.6 (5-C), 36.1 (2-C), 32.5 (3-CH<sub>2</sub> Bu), 20.3 (2-CH<sub>2</sub> Bu), 13.9 (CH<sub>3</sub> Bu). MS: 413.3 [M+1]<sup>+</sup>. Anal. cal. for C<sub>24</sub>H<sub>32</sub>N<sub>2</sub>O<sub>4</sub>: C 69.88, H 7.82, N 6.79, found C 69.98, H 7.93, N 6.55.

#### General Procedure for the Cyclization to 2-pyrrolidinones

Diamino ester derivatives (0.2 mmol) were dissolved in MeOH (10 mL) and a catalytic amount of Pd/C (10% w/w) and HCl (35%) (0.2 mmol) were added. The reaction was kept under 20 psi of H<sub>2</sub> for 2 h at room temperature. The suspension was filtered and evaporated. Then, the residue was dissolved in toluene (5 mL) and TEA (28  $\mu$ L, 0.2 mmol) was added. The reaction was heated at 110°C for 2 hours. After evaporation, the residue was dissolved in EtOAc and washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum. The resulting residue was purified on a silica gel column using the solvents indicated in each case.

## (4S\*,5S\*,1'S\*)-5-Benzyl-4-[(1'-(tert-

#### butoxycarbonyl)ethyl]amino-2-pyrrolidinone (7a)

Eluent: CH<sub>2</sub>Cl<sub>2</sub>:MeOH (50:1). 46% (oil). HPLC  $t_{\rm R} = 6.24$  min (20 to 100% A in 20 min).<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$ :7.33–7.17 (m, 5H, H Ar), 5.46 (bs, 1H, 1-NH), 3.81 (dddd, 1H,  $\mathcal{J} = 11.1$ , 6.7, 3.4, 0.7 Hz, 5-H), 3.56 (m, 1H,  $\mathcal{J} = 9.3$ , 7.8, 6.7 Hz, 4-H), 3.22 (q, 1H,  $\mathcal{J} = 7.0$  Hz, 1'-H), 2.98 (dd, 1H,  $\mathcal{J} = 13.5$ , 3.4 Hz, 5-CH<sub>2</sub>), 2.58 (dd, 1H,  $\mathcal{J} = 13.5$ , 11.1 Hz, 5-CH<sub>2</sub>), 2.47 (dd, 1H,  $\mathcal{J} = 16.4$ , 7.8 Hz, 3-H), 2.28 (dd, 1H,  $\mathcal{J} = 16.4$ , 9.3 Hz, 3-H), 1.81 (bs, 1H, 4-NH), 1.48 (s, 9H, CH<sub>3</sub> 'Bu), 1.29 (d, 3H,  $\mathcal{J} = 7.0$ , 2'-H).<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ : 175.1, 174.9 (CO), 138.0, 129.8, 128.8, 126.7 (*C* and CH Ar), 81.5 (C 'Bu), 58.8 (5-C), 56.5 (1'-C), 55.5 (4-C), 36.6 (3-C), 36.4 (5-CH<sub>2</sub>), 28.0 (CH<sub>3</sub> 'Bu), 19.5 (2'-C). MS: 319.5 [M+1]<sup>+</sup>. Anal. cal. for C<sub>18</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>: C 67.90, H 8.23, N 8.80, found C 67.89, H 7.94, N 8.72.

## (4*R*\*,5*S*\*,1'*S*\*)-5-Benzyl-4-[(1'-(*tert*-

#### butoxycarbonyl)ethyl]amino-2-pyrrolidinone (7b)

Eluent: CH<sub>2</sub>Cl<sub>2</sub>:MeOH (40:1). 40% (oil). HPLC  $t_{\rm R} = 7.12$  min (20 to 100% A in 20 min).<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$ :7.28-7.10 (m, 5H, H Ar), 5.59 (bs, 1H, 1-NH), 3.51(dt, 1H,  $\mathcal{J}$ = 9.0, 4.6 Hz, 5-H), 3.15(m, 1H, 4-H), 3.11 (q, 1H,  $\mathcal{J}$ = 7.0 Hz, 1'-H), 2.95 (dd, 1H,  $\mathcal{J}$ = 13.5, 4.6 Hz, 5-CH<sub>2</sub>), 2.56 (dd, 1H,  $\mathcal{J}$ = 13.5, 9.0 Hz, 5-CH<sub>2</sub>), 2.46 (dd, 1H,  $\mathcal{J}$ = 16.8, 7.6 Hz, 3-H), 2.12 (dd, 1H,  $\mathcal{J}$ = 16.8, 6.3 Hz, 3-H), 1.75 (bs, 1H, 4-NH), 1.40 (s, 9H, CH<sub>3</sub> 'Bu), 1.16 (d, 3H,  $\mathcal{J}$ = 7.0, 2'-H).<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ : 175.3, 174.9 (CO), 136.9, 129.1, 129.0, 128.6, 126.8 (*C* Ar), 81.4 (C 'Bu), 62.1 (5-*C*), 57.5 (4-*C*), 54.9 (1'-*C*), 41.0 (5-*C*H<sub>2</sub>), 37.7 (3-*C*), 28.0 (CH<sub>3</sub> 'Bu), 19.4 (2'-*C*). MS: 319.4 [M+1]<sup>+</sup>. Anal. cal. for C<sub>18</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>: C 67.90, H 8.23, N 8.80, found C 68.01, H 8.40, N 8.61.

## (4*S*\*,5*S*\*,1'*R*\*)-5-Benzyl-4-[(1'-(*tert*butoxycarbonyl)ethyl]amino-2-pyrrolidinone (7c)

Eluent: CH<sub>2</sub>Cl<sub>2</sub>:MeOH (50:1). 48% (oil). HPLC  $t_{\rm R} = 6.28$  min (20 to 100% A in 20 min).<sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$ :7.27–7.10 (m, 5H, H Ar), 5.35 (bs, 1H, 1-NH), 3.84 (dddd, 1H,  $\mathcal{J} = 11.2$ , 6.5, 3.4, 0.8 Hz, 5-H), 3.64 (m, 1H 4-H), 3.28 (q, 1H,  $\mathcal{J} = 6.9$ , 1'-H), 2.95 (dd, 1H,  $\mathcal{J} = 13.5$ , 3.4 Hz, 5-CH<sub>2</sub>), 2.55 (dd, 1H,  $\mathcal{J} = 13.5$ , 11.2 Hz, 5-CH<sub>2</sub>), 2.47 (dd, 1H,  $\mathcal{J} = 16.4$ , 7.3 Hz, 3-H), 2.28 (dd, 1H,  $\mathcal{J} = 16.4$ , 8.1 Hz, 3-H), 1.69 (bs, 1H, 4-NH), 1.41 (s, 9H, <sup>'</sup>Bu), 1.24 (d, 3H,  $\mathcal{J} = 6.9$ , 2'-H).<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$ : 175.1, 174.8 (CO), 137.9, 129.1, 128.9, 126.8 (C Ar), 81.5 (C <sup>'</sup>Bu), 58.9 (5-C), 55.2 (1'-C), 54.5 (4-C), 36.6 (3-C), 36.2 (5-CH<sub>2</sub>), 28.1 (CH<sub>3</sub> <sup>'</sup>Bu), 19.4 (2'-C). MS: 319.4 [M+1]<sup>+</sup>. Anal. cal. for C<sub>18</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>: C 67.90, H 8.23, N 8.80, found C 67.63, H 8.10, N 8.55.

## (4*S*\*,5*S*\*)-5-Benzyl-4-[(*tert*-butoxycarbonyl)methyl]amino-2-pyrrolidinone (8a)

Eluent: CH<sub>2</sub>Cl<sub>2</sub>:MeOH (40:1). 40% (oil). HPLC  $t_{\rm R} = 6.29$  min (20 to 100% A in 20 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>) &: 7.27-7.11 (m, 5H, H Ar), 5.38 (bs, 1H, 1-NH), 3.81 (dddd, 1H,  $\mathcal{J} = 11.1$ , 6.6, 3.4, 0.8 Hz, 5-H), 3.56 (m, 1H,  $\mathcal{J} = 8.4$ , 7.5, 6.6 Hz, 4-H), 3.28 (bs, 2H, CH<sub>2</sub> Gly), 2.94 (dd, 1H,  $\mathcal{J} = 13.5$ , 3.5 Hz, 5-CH<sub>2</sub>), 2.56 (dd, 1H,  $\mathcal{J} = 13.5$ , 11.1 Hz, 5-CH<sub>2</sub>), 2.45 (dd, 1H,  $\mathcal{J} = 16.5$ , 7.5 Hz, 3-H), 2.25 (dd, 1H,  $\mathcal{J} = 16.4$ , 8.4 Hz, 3-H), 1.77 (bs, 1H, 4-NH), 1.42 (s, 9H, CH<sub>3</sub> 'Bu), <sup>13</sup>C NMR (CDCl<sub>3</sub>) &: 174.8, 171.1 (CO), 137.7, 129.1, 128.9, 126.8 (C and CH Ar), 81.3 (C 'Bu), 58.7 (5-C), 56.3 (4-C), 50.0 (CH<sub>2</sub> Gly), 36.4 (3-C), 36.2 (5-CH<sub>2</sub>), 28.1 (CH<sub>3</sub> 'Bu). MS: 305.5 [M+1]<sup>+</sup>. Anal. cal. for C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>: C 67.08, H 7.95, N 9.20, found C 66.86, H 8.08, N 8.97.

## (4*R*\*,5*S*\*)-5-Benzyl-4-[(*tert*-butoxycarbonyl)methyl]amino-2-pyrrolidinone (8b)

Eluent: CH<sub>2</sub>Cl<sub>2</sub>:MeOH (40:1). 43% (oil).HPLC  $t_{\rm R}$  = 7.23 min (20 to 100% A in 20 min). <sup>1</sup>H NMR (CDCl<sub>3</sub>) & 7.35–7.18 (m, 5H, H Ar), 5.80 (bs, 1H, 1-N*H*), 3.67 (m, 1H, 5-*H*), 3.26 (m, 3H, C*H*<sub>2</sub> Gly, 4-*H*), 3.00 (dd, 1H,  $\mathcal{J}$ =13.6, 4.9 Hz, 5-C*H*<sub>2</sub>), 2.67 (dd, 1H,  $\mathcal{J}$ =13.6, 8.8 Hz, 5-C*H*<sub>2</sub>), 2.59 (dd, 1H,  $\mathcal{J}$ =17.0, 7.6 Hz, 3-*H*), 2.21 (dd, 1H,  $\mathcal{J}$ =17.0, 5.4 Hz, 3-*H*), 1.46 (s, 9H, CH<sub>3</sub> 'Bu). <sup>13</sup>C NMR (CDCl<sub>3</sub>) & 175.1, 171.1 (CO), 137.1, 129.0, 128.9, 127.0 (*C* and *C*H Ar), 81.8 (C 'Bu), 61.89 (5-*C*), 58.8 (4-*C*), 49.3 (*C*H<sub>2</sub> Gly), 41.3 (5-*C*H<sub>2</sub>), 37.5 (3-*C*), 28.0 (CH<sub>3</sub> 'Bu). MS: 305.4 [M+1]<sup>+</sup>. Anal.

#### References

- Nugent TC, El-Shazly M (2010) Chiral amine synthesis Recent developments and trends for enamide reduction, reductive amination, and imine reduction. Adv Synth Catal 352: 753–819.
- Tripathi RP, Verma SS, Pandley J, Tiwari VK (2008) Recent development on catalytic reductive amination and applications. Curr Org Chem 12: 1093–1115.
- Gomez S, Peters JA, Maschmeyer T (2002) The reductive amination of aldehydes and ketones and the hydrogenation of nitriles: Mechanistic aspects and selectivity control. Adv Synth Catal 344: 1037–1057.
- Abdel-Magid AF, Mchrman SJ (2006) A review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes. Org Proc Res Develop 10: 971–1031.
- Shibata I, Suwa T, Sugiyama T, Baba A (1998) Dibutyltin chloride hydride complex as a novel reductant for chemoselective reductive amination. Synlett: 1081–1082.
- Lee O-Y, Law K-L, Yang D (2009) Secondary amine formation from reductive amination of carbonyl compounds promoted by Lewis acid using the InCl<sub>3</sub>/ Et<sub>3</sub>SiH system. Org Lett 11: 3302–3305.
- Gautier F-M, Jones S, Li X, Martin SJ (2011) Scope of the organocatalysed asymmetric reductive amination of ketones with trichlorosilane. Org Biomol Chem. 9: 7860–7868.
- Lelais G, Seebach D (2004) β2-Amino acids syntheses, occurrence in natural products, and components of β-peptides. Biopolymers 76: 206–243.
- 9. Kuhl A, Hahn MG, Dumic M, Mittendorf J (2005) Alicyclic  $\beta$ -amino acids in medicinal chemistry. Amino acids 29: 89–100.

cal. for  $\rm C_{17}H_{24}N_2O_3:$  C 67.08, H 7.95, N 9.20, found C 66.98, H 7.69, N 8.79.

# Supporting Information

Figure S1 Chiral HPLC chromatograms for 1 and 3a.  $(\mathrm{PDF})$ 

Figure S2 Chiral HPLC chromatograms for 4a and 6a.  $(\mbox{PDF})$ 

Figure S3 <sup>1</sup>H NMR spectra for monitoring the intermediate formation.

(PDF)

Figure S4 <sup>1</sup>H NMR spectra of deuterated diamino esters 3a-3c.

(PDF)

Figures 85 <sup>1</sup>H NMR spectra of deuterated diamino esters 4a–4b.

(PDF)

**Figure S6** X-Ray packing of compound 7a. (PDF)

**Figure S7** X-Ray packing of compound 7b. (PDF)

Figure S8 NMR Spectra for new compounds 2–8 (PDF)

Table S1Direct reductive amination trials.(PDF)

Table S2Indirect reductive amination experiments.(PDF)

## Acknowledgments

Dedicated to Professor José Luis García-Ruano on the occasion of his 65th birthday

## **Author Contributions**

Conceived and designed the experiments: RGM AFM. Performed the experiments: PPF MTA LI AFC. Analyzed the data: RGM JMGR AFM LI. Contributed reagents/materials/analysis tools: RGM MTGL JMGR AFM LI. Wrote the paper: RGM MTGL.

- 10. Cimarelli C, Palmieri G (1996) Stereoselective reduction of enantiopure  $\beta$ enamino esters by hydride: A convenient synthesis of both enantiopure  $\beta$ -amino esters J Org Chem 1996, 61: 5557–5563.
- 11. Nugent TC, Ghosh AK (2007) Selective synthesis of unnatural  $\alpha\text{-},$   $\beta\text{-}$  and  $\gamma\text{-}$  amino esters. Eur J Org Chem 72: 3863–3869.
- Wang C, Pettman A, Bacsa J, Xiao J (2010) A versatile catalyst for reductive amination by transfer hydrogenation. Angew Chem Int Ed 49: 7548–7552.
- 13. Bunlaksananusorn T, Rampf F (2005) A facile one-pot synthesis of chiral  $\beta$ -amino esters. Synlett: 2682–2684.
- 14. Kim H-O, Carroll B, Lee MS (1997) Preparation and synthetic applications of sterically hindered secondary amines. Synth Commun 27: 2505–2515.
- Xu D, Prasad K, Repic O, Blacklock TJ (1997) A practical synthesis of enantiopure ethyl *cis*-2-amino-1-cyclohexanecarboxylate via asymmetric reductive amination methodology. Tetraedron: Asymmetry 8: 1445–1451.
- Lee H-S, LePlae PR, Porter EA, Gellman SH (2001) An efficient route to either enantiomer of orthogonally protected trans-3-aminopyrrolidine-4-carboxylic acid. J Org Chem 66: 3597–3599.
- 17. Busscher GF, Lefort L, Cremers JGO, Mottinelli M, Wiertz RW, et al. (2010) Efficient preparation of an N-aryl  $\beta$ -amino acid via asymmetric hydrogenation and direct asymmetric reductive amination en route to Ezetimibe. Tetraedron: Asymmetry 21: 1709–1714.
- Fellah M, Santarem M, Lhommet G, Mouriès-Mansuy V (2010) Total synthesis of quinolizidine (-)-217A. J Org Chem 75: 7803–7808.
- Zivec M, Jakopin Z, Gobec S (2009) Recent advances in the synthesis and applications of reduced amide pseudopeptides. Curr Med Chem 16: 2289–2304.

- Abdel-Magid AF, Carson KG, Harris BD, Maryanoff CA, Shah RD (1996) Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J. Org Chem 61: 3849–3862.
- Setoi H, Kayakiri H, Hashimoto M (1989) Diastereoselective synthesis of an α,βdiaminocarboxylic acid: an efficient synthesis of FR900490, an immunomodulating peptide isolated from a fungus. Chem Pharm Bull 37: 1126–1127.
- Gómez-Monterrey I, González-Muñiz R, Herranz R, García-Lopez MT (1993) Stereospecific synthesis of (2R,35)-3-amino-2-piperidineacetic acid derivatives for use as conformational constraint in peptides. Tetrahedron Lett 34: 3593–3594.
- Patiño-Molina R, Herranz R, García-López MT, González-Muñiz R (1999) Stereoselective reductive amination of β-keto esters derived from dipeptides. Stereochemical and mechanistic studies on the formation of 5-carboxymethyl-2oxopiperazine derivatives. Tetrahedron 55: 15001–15010.
- Martín-Martínez M, Bartolomé-Nebreda JM, Gómez-Monterrey I, González-Muñiz R, García-López MT, et al. (1997) Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists. J Med Chem 40: 3402–3407.
- Patiño-Molina R, García-López MT, Cenarruzabeitia E, Del Río J, González-Muñiz R (2007) Simple approach to highly functionalized trisubstituted tetrahydropyrimidine-2,4-diones from perhydropyrazino[1,2-f]pyrimidine-3,6,8-trione precursors. Synthesis: 1047–1053.
- Patiño-Molina R, Martín-Martínez M, Herranz R, García-López MT, González-Muñiz R (2000) Studies on the synthesis of β-keto esters derived from dipeptides: search for a low-epimerizing method. Lett Peptide Sci 7: 143– 149.
- Nugent TC, Ghost AK, Wakchaure VN, Mohanty RR (2006) Asymmetric reductive amination: convenient access to enantioenriched alkyl-alkyl or arylalkyl substituted α-chiral primary amines. Adv Synth Catal 348: 1289–1299.
- Sridharan V, Avendaño C, Menéndez JC (2007) General, mild and efficient synthesis of β-enaminones catalyzed by ceric ammonium nitrate. Synlett: 881– 884.
- Lenin R, Raju M (2007) Lanthanum trichloride: an efficient Lewis acid catalyst for chemo- and regioselective enamination of β-dicarbonyl compounds. Arkivoc xiii: 204–209.
- Kim S, Oh CH, Ko JS, Ahn KH, Kim YJ (1985) Zinc-modified cyanoborohydride as a selective reducing agent. J Org Chem 50: 1927–1932.

- Nugent TC, Negru DE, El-Shazly M, Hu D, Sadiq A, et al. (2011) Sequential reductive amination-hydrogenolysis: A one-pot synthesis of challenging chiral primary amines. Adv Synth Catal 353: 2085–2092.
- Belot S, Sulzer SK, Alexakis A (2008) Enantioselective organocatalytic conjugate addition of α-aminoketones to nitroolefins. Chem Commun 4694–4696.
- Fitch DM, Evans KA, Chai D, Duffy KJ (2005) A highly efficient asymmetric synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Org Lett 7: 5521–5524.
- Wen JJ, Spatola AF (1997) A systematic approach to the solid-phase synthesis of linear and cyclic pseudopeptide libraries containing [CH<sub>2</sub>NH] amide bond surrogates. J. Peptide Sci 49: 3–14.
- Li X, Ydin AK (2007) Epimerization- and protecting-group-free synthesis of peptidomimetic conjugates from amphoteric amino aldehydes. J Am Chem Soc 129: 14152–14153.
- Iden HS, Lubell WD (2008) 1,3,5-Tri and 1,3,4,5-tetra-substituted 1,4-diadepin-2-one solid-phase synthesis. J Comb Chem 10: 691–699.
- Hoang CT, Bouillère F, Johannesen S, Zulauf A, Panel C, et al. (2009) Amino acid homologation by the Blaise reaction: a new entry into nitrogen heterocycles. J Org Chem 74: 4177–4187.
- Bisol TB, Bortoluzzi AJ, Sá MM (2011) Nucleophilic ring-opening of epoxide and aziridine acetates for the stereodivergent synthesis of β-hydroxy and βamino γ-lactams. J Org Chem 76: 948–962.
- Davies SG, Lee JA, Roberts PM, Thomson JE, Yin J (2012) Parallel kinetic resolution of acyclic γ-amino-α,β-unsaturated esters: Application to the asymmetric synthesis of 4-aminopyrrolidin-2-ones. Org Lett 14: 218–221.
- 40. (a) Nardelli M (1983) PARST: a system of FORTRAN routines for calculating molecular structure parameters from results of crystal structure analyses. Comput Chem 7: 95–98. (b) Nardelli M J (1995) PARST95 - an update to PARST: a system of Fortran routines for calculating molecular structure parameters from the results of crystal structure analyses. Appl Cryst 28: 659.
- Mansour TS, Evans CA (1990) Decarboxylative carbon acylation of malonates with aminoacylimidazolides mediated by Lewis acids. Synth Commun 20: 773– 781.
- Theberge CR, Zercher CK (2003) Chain extension of amino acid skeletons: Preparation of ketomethylene isosteres. Tetrahedron 59: 1521–1527.
- Devant RM, Radunz H-E (1988) A novel short and efficient asymmetric synthesis of statine analogs. Tetrahedron Lett 29: 2307–2310.